App-Quantinova.ai

B-Raf inhibition-induced paradoxical activation of MEK/ERK signaling enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells

You-Take Oh - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Vemurafenib

Predicting cellular response to small molecule Mcl-1 antagonists

Leah Hogdal - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Small molecule Mcl-1 inhibitors induce apoptosis and death in multiple cancer subtypes in vitro

John L. Sensintaffar - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Navitoclax

Targeting MCL-1 expression, through the inhibition of CDK9 and super enhancer driven transcription, offers multiple opportunities for rational drug combinations

Wontak Kim - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

5-Azacytidine

Novel radiation mitigators and anticancer drugs

Robert H. Schiestl - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Preclinical evaluation of Rad6 inhibition to overcome platinum resistance in ovarian cancer

Sebastian M. Spencer - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Solid malignancies

Carboplatin

Schlafen 11 (SLFN11) blocks RNA synthesis upon replicative damage, a novel mechanism for killing cancer cells in response to DNA damaging agents

Junko Murai - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

camptothecin

Antimetastatic activity of ISTH0047, a potent and selective TGF-beta 2 antisense oligonucleotide, in syngeneic lung metastatic model of mouse 4T1 mammary carcinoma

Katja Wosikowski - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Solid malignancies

N/A

New non-integrative MS2-based lentiviral particles for mRNA delivery: A safe and efficient opportunity for gene editing and immunotherapy applications

Pascale Bouille - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Targeted therapy for breast cancer bone metastases using mRNA engineered mesenchymal stem cells

Aude Segaliny - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Tumor fibroblast targeting via uPAR retargeted measles virus: In vitro and in vivo effects

Yuqi Jing - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A high dose priming strategy with the novel RNAi therapeutic GS-10 elevates RISC Ago2, Ago4 and GW182 protein levels to enhance RNAi efficacy in a metastatic solid tumor model

Lucas P. Nacusi - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

GS10

CD133-targeted oncolytic adenovirus shows therapeutic effect by attacking colon cancer stem cells

Mizuho Sato - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Apoptosis inducer gene delivery by polylysine-calcium complexes attenuates mouse lung carcinoma allograft growth after intravenous injection or intratracheal spray

Susumu Ishiguro - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Calcium Chloride

A novel class of chemicals that react with damaged DNA and specifically kill B-cell cancers

Shanqiao Wei - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Trabectedin activity in patient-derived mesothelioma xenografts

Simonetta Andrea Licandro - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

Trabectedin

Targeting promoter regions of c-Myc and Bcl-2 in AML cells using G-quadruplex interacting drugs

Megan Turnidge - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cytarabine liposomal

Targeting of epithelial-to-mesenchyme transition by a novel small molecule inhibitor attenuates prostate and breast cancer invasiveness and bone metastases

Jan Kroon - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Continuous, low intensity systemic dosing maximizes the therapeutic margin of Eg5/KSP inhibition in an orthotopic model of urothelial cell carcinoma

Leigh Williams - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

HEXIM1 as a pharmacodynamic marker for monitoring target engagement of ABBV-075

Xiaoli Huang - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

abbv-075

Filters

41730 Abstracts